EUVIMEDEUVIMED entdecken
Open Access

Outcomes and relapse patterns in primary central nervous system lymphoma: Longitudinal analysis of 559 patients diagnosed from 1983 to 2020

Kathryn R Tringale iD, Michael Scordo iD, Joachim Yahalom iD, Charlie White, Zhigang Zhang, Behroze Vachha, Gustav Cederquist, Lauren Schaff, Lisa DeAngelis, Christian Grommes, Brandon S Imber iD

Neuro-Oncology · 2024

DOI: 10.1093/neuonc/noae115 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, 2024. Verfasst von Kathryn R Tringale und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA. Hauptthemen laut MEDLINE: Central Nervous System Neoplasms, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Contemporary outcomes and relapse patterns in primary CNS lymphoma (PCNSL) are lacking. We analyzed factors associated with relapse in a large cohort with extensive follow-up.

Methods

T1-post-contrast-enhancing disease was characterized in immunocompetent PCNSL (diffuse large B-cell) patients from 1983 to 2020. Patients were stratified by response to induction and consolidation (complete/unconfirmed [CR/CRu], partial, stable, progression [POD]). Refractory was POD during (or relapse ≤3 months of) induction. Initial relapse site was categorized as local (involving/adjacent to baseline), distant intraparenchymal, leptomeningeal, or other. Progression-free (PFS) and overall survival (OS) were assessed with proportional hazards. Cumulative incidence with competing risks was used to assess local relapse.

Results

Median follow-up was 7.4 years (N = 559). Most (321, 57%) were recursive partitioning analysis class 2 (age ≥50, Karnosfky Performance Status [KPS] ≥70). Most had supratentorial (420, 81%), multifocal (274, 53%), bilateral (224, 43%), and deep structure involvement (314, 56%). Nearly all received methotrexate-based induction (532, 95%). There was no difference in PFS or OS from consolidation based on initial response to induction (CR/CRu vs PR) in patients who ultimately achieved a CR/CRu to consolidation. PFS at 1-, 5 years for 351 patients with CR/CRu to consolidation was 80% (95% confidence interval [95% CI]: 76%–84%) and 46% (95% CI: 41%–53%), respectively; 1-year cumulative incidence of local versus nonlocal relapse was 1.8% versus 15%, respectively. For 97 refractory patients, 1-year cumulative incidence of local versus nonlocal relapse was 57% versus 42%, respectively. Deep structure involvement (HR 1.89, 95% CI: 1.10%–3.27%) was associated with local relapse in refractory patients.

Conclusions

We report the first comprehensive relapse patterns in a large PCNSL cohort. While relapses post-CR to consolidation are typically distant and unpredictable, refractory patients had a relatively high incidence of local relapse. These findings can help optimize multimodality therapy for this highest-risk population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Central Nervous System NeoplasmsNeoplasm Recurrence, LocalHumansMaleFemaleMiddle AgedAgedAdultFollow-Up StudiesLongitudinal StudiesSurvival RateYoung AdultLymphoma, Large B-Cell, DiffuseAged, 80 and overPrognosisAdolescentRetrospective StudiesAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

consolidationimagingpatterns of failureprimary central nervous system lymphomaradiation therapy

Autor:innen und Institutionen

  • Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Department of Radiation Medicine and Applied Sciences, University of California San Diego, San Diego, California, USA.
  • Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Department of Radiology, UMass Chan Medical School, Worcester, Massachusetts, USA.
  • Department of Neurology/Neuro-oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

ORCID-Profile: Kathryn R Tringale, Michael Scordo, Joachim Yahalom, Brandon S Imber

Förderung

  • NCI NIH HHS
  • NIH HHS
  • National Institutes of Health
  • Lacher Lymphoma Foundation
  • Connecticut Cancer Foundation

Zitieren

APA

Tringale, K. R., Scordo, M., Yahalom, J., White, C., Zhang, Z., Vachha, B., Cederquist, G., Schaff, L., DeAngelis, L., Grommes, C., & Imber, B. S. (2024). Outcomes and relapse patterns in primary central nervous system lymphoma: Longitudinal analysis of 559 patients diagnosed from 1983 to 2020. Neuro-Oncology. https://doi.org/10.1093/neuonc/noae115

Vancouver

Tringale KR, Scordo M, Yahalom J, White C, Zhang Z, Vachha B, et al. Outcomes and relapse patterns in primary central nervous system lymphoma: Longitudinal analysis of 559 patients diagnosed from 1983 to 2020. Neuro-Oncology. 2024. doi:10.1093/neuonc/noae115

BibTeX
@article{Tringale2024,
  author = {Tringale, Kathryn R and Scordo, Michael and Yahalom, Joachim and White, Charlie and Zhang, Zhigang and Vachha, Behroze and Cederquist, Gustav and Schaff, Lauren and DeAngelis, Lisa and Grommes, Christian and Imber, Brandon S},
  title = {Outcomes and relapse patterns in primary central nervous system lymphoma: Longitudinal analysis of 559 patients diagnosed from 1983 to 2020},
  journal = {Neuro-Oncology},
  year = {2024},
  doi = {10.1093/neuonc/noae115}
}
Kostenlos starten →